Epitracker leverages genomic, metabolomic, and complex lipidomic data from previously collected and archived dolphin samples to discover novel small molecule therapeutics that may continually improve the health and welfare of dolphins and humans across four primary programs: Longevity, Neurodegenerative Diseases, Fibrotic Diseases, and Pulmonary Diseases.
Read below to learn how Epitracker discovers and screens its compounds.
Read below to learn how Epitracker discovers and screens its compounds.
Step 1: Screen for Promising Molecules
Our discovery process starts with the analysis of millions of metabolomic, lipid, genomic and clinical data points generated from previously collected, archived dolphin samples using tiered statistical models to prioritize which small molecules predict healthy dolphins. This prioritization is based on each molecule's potential as a candidate therapeutic, therapeutic target, and/or biomarker across our discovery programs. These 'smart screened' molecules become part of Epitracker's rapidly expanding compound libraries that are further screened, prioritized and advanced as therapeutic candidates.
Step 2: Prioritize and Place Molecules in Compound LibrariesEpitracker's discovery platform has yielded hundreds of promising molecules across more than 30 pathways. These compounds include lipids, amino acids, and other molecules that are known or expected to be present in human serum.
Today, Epitracker has compound libraries for longevity, neurodegenerative diseases, nonalcoholic steatohepatitis, and pulmonary diseases. |
|
Step 3: Test Molecules for Activity & Efficacy
Once Epitracker's smart-screened molecules have been prioritized and placed into a compound library, we advance them through our discovery-to-product process. To date, 18 of 20 - that's an impressive 90% of our molecules tested - have successfully demonstrated desired dose-response activity in human cell systems. Based on encouraging cell-based activity, mechanism of action, associated genetic & pathway, and bench marking data, eight of our compounds are being advanced through the appropriate Epitracker program.
